Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

3SBio and Sorrento Therapeutics Form $10 Million China JV for CAR-T Drugs

publication date: Jun 7, 2016
3SBio of Shenyang and Sorrento Therapeutics, a US-China biopharma, formed a joint venture to develop CAR-T drugs in China. 3SBio will invest $10 million in the JV, and Sorrento will contribute China rights to its clinical-stage CAR-T cancer treatment and two other CAR-T therapies. 3SBio will own 51% of the JV, with the remainder belonging to Sorrento. The agreement will be carried out between 3SBio's subsidiary, Shenyang Sunshine Pharmaceutical, and Sorrento's China subsidiary, TNK Therapeutics. More details....

Stock Symbols: (HK: 1530) (NSDQ: SRNE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital